Get started

Pharmaceuticals

Lupin Long-Term Investment IdeaAs we can see on the month chart stock breakout it rounding bottom after a many years with very good volume and retesting. Bullish crossover on November 2023 Technical Analysis & indicators 🔍 Monthly Chart Rounding Bottom Educational content 📖 This stock analysis is designed for educational purposes and should not be taken as financial advice. Please carry out your own research or consult with a financial advisor before investing. Visit the website and check fundamental
NSE:LUPINLong
by SHEHBAZ_KHAN
ELI LILLY: This consolidation is a buy opportunity.Eli Lilly is neutral on its 1D technical outlook (RSI = 52.880, MACD = 1.910, ADX = 25.797) as well as on 1W as for the past 7 weeks it has turned sideways. This consolidation is taking place half-way through the new bullish wave of the Channel Up that started in early 2023. As you see it is supported by the 1W MA50 and every bullish wave in the beginning was almost at +50% but the latest one was +35%. Consequently we expect a minimum of +46.22% from the bottom and that's what we're aiming for (TP = 1,095). See how our prior idea has worked out: ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:LLYLong
by InvestingScope
ELI LILLY Always a solid buy below its 1D MA50.Eli Lilly (LLY) broke on Friday below its 1D MA50 (blue trend-line) for the first time since August 09. As the stock trades within a long-term Channel Up since the March 01 2023 bottom, every time the price was below the 1D MA50, it didn't stay for long, thus providing the most effective buy entry. Even though it could dip some more as with July's decline (only such case though out of 6 corrections), as long as the 1D MA200 (orange trend-line) holds, we expect the Channel Up to be extended. The initial Higher Highs were closer to the 1.5 Fibonacci Channel extension, the last one however was exactly on the 1.0 Fib. As a result, we will take a more conservative Target on that trend-line, thus turning bullish now and aiming at $1100 by the end of the year. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
Sanofi (SNY): A Strong Investment CaseCompany Overview: Sanofi NASDAQ:SNY is a major pharmaceutical company based in Paris, with a market capitalization of $134 billion. Investment Highlights: Dividend Yield: 3.8%, more than double the S&P 500 average. Drug Portfolio: Diverse and includes successful drug developments. Pipeline: Promising future drug pipeline with potential for growth. Berkshire Hathaway Investment: Long-standing investment from Berkshire Hathaway underscores the company’s attractiveness and stability. Outlook: We are bullish on SNY due to its growth potential and solid dividend payout. The combination of a strong drug portfolio, promising pipeline, and robust dividend makes Sanofi a compelling investment choice. #Sanofi #SNY #Pharmaceuticals #Investment #DividendYield #MarketCap #GrowthPotential #BerkshireHathaway #StockAnalysis #Bullish
NASDAQ:SNYLong
by Richtv_official
ELI LILLY Recovered all losses from its High! What's next?Eli Lilly and Company (LLY) posted a miraculous bullish reversal in the past 2 weeks, recovering yesterday all of the losses of the brutal correction since its July 15 All Time High. Having rebounded on its 1D MA200 (orange trend-line) while the 1D RSI touched the 30.00 oversold barrier for the first time since February 28 2023, we can claim that LLY's Channel Up now sets eyes for its next Higher High. This pattern is best illustrated with the use of the Fibonacci Channel levels. After initially holding the 1.0 Fib as Resistance, the 'ceiling' is now the 1.5 Fib extension, basically has been since September 12 2023. The interesting parameter of this pattern is that every approximately +35.00 to +40.00% rise, the price pulls back or turns sideways (red arc pattern) until it eventually hits the 1D MA50 (blue trend-line). As the stock completes a +35% rise from the bottom, a little above the 1000 mark, we expect it to turn sideways at best. The target after that is $1200, exactly on the 1.0 Fibonacci level, which is still a modest one, considering that the ceiling is now the 1.5 Fib extension, as discussed above. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
Axsome Therapeutics - A Pennant Primed to RiseAxsome - NASDAQ:AXSM ✅In position since Feb 2023 with average price $50.00 per share. This is a long term 3 - 5 year hold. ✅ Current unrealized gain at 75% ✅ Stop Loss set at $63.80 for 50% of the position to ensure short term gain capture ⏳We awaiting increasing levels of volume (see the green zone). Volume moving into this zone would be ideal and demonstrate increased interest ⏳The On Balance Volume (OBV) has demonstrated that is consolidates in parallel channels and when it breaks out of them it signals price direction. We can watch the OBV for direction The chart still looks great and we are sitting in a nice profit position with short term profits guaranteed by a stop. The OBV will be key to watch. I still think this company is ripe for a buy out. Background of Axsome Therapeutics AXSM are a Small Bio-Pharma company with market cap of $4.24 Billon. In August 2022 Auvelity Anti-Depressants was FDA approved & is the only rapid-acting oral medicine for MDD with labelling describing statistically significant antidepressant efficacy by one week. AXSM received Breakthrough Therapy designation from the FDA for an Alzheimer's disease drug development and are at the NDA phase for developing a drug for acute treatment of migraine. AXSM are also developing a treatment for narcolepsy and separately for fibromyalgia. All in, AXSM's offerings are building momentum. They have developed the fastest acting anti-depressant drug and are bringing it to market, and have a four other drugs in development, all of which have a large patient base. The company would be ripe for a buyout. PUKA
NASDAQ:AXSMLong
by PukaCharts
1
SWING IDEA - GLAXO SMITHKLINE PGlaxoSmithKline Pharmaceuticals , a major player in the pharmaceutical industry, is displaying technical signals that suggest a potential swing trade opportunity. Reasons are listed below : Breakthrough of Strong Resistance (1800-1900) : The 1800-1900 range was a significant resistance level. The price has broken through, retested, and is now making new highs, indicating strong bullish momentum. Breaking a 9+ Year Consolidation Phase : The stock has emerged from a consolidation phase that lasted over 9 years, signaling a potential new long-term bullish trend. Bullish Engulfing Candle on Weekly Timeframe : The recent bullish engulfing candle on the weekly chart indicates a significant shift towards bullish sentiment, engulfing the previous week's candle and suggesting further upward movement. 0.5 Fibonacci Support : The stock has found support at the 0.5 Fibonacci retracement level, reinforcing the potential for a continued bullish trend after a retracement. Increased Volumes : A noticeable increase in trading volumes confirms the strength of the price move, indicating strong investor interest and participation in the current trend. Trading at All-Time High : The stock is trading at its all-time high, suggesting strong market confidence and the potential for further gains. However, it's also important to monitor for signs of overextension or profit-taking at these levels. Target - 2940 // 3600 Stoploss - weekly close below 1950 DISCLAIMER - Decisions to buy, sell, hold or trade in securities, commodities and other investments involve risk and are best made based on the advice of qualified financial professionals. Any trading in securities or other investments involves a risk of substantial losses. The practice of "Day Trading" involves particularly high risks and can cause you to lose substantial sums of money. Before undertaking any trading program, you should consult a qualified financial professional. Please consider carefully whether such trading is suitable for you in light of your financial condition and ability to bear financial risks. Under no circumstances shall we be liable for any loss or damage you or anyone else incurs as a result of any trading or investment activity that you or anyone else engages in based on any information or material you receive through TradingView or our services. @visionary.growth.insights
NSE:GLAXOLong
by Visionary_Growth_Insights
Momentum Trading Picks - Pharma Stock Natco Pharma.This chart is very interesting as well as confusing at the same time for some people let's break it down step by step. If you see the monthly chart of Natco Pharma you will notice many patterns there like:- Cup pattern W pattern Pole and flag Pattern Volume is increasing significantly on the monthly chart Breakout already happened last week but those who are willing to take risks can still participate in it because the stop loss will be a bit on the higher side.
NSE:NATCOPHARMLong
by mittalanugrahit
Index to watchout for next week: Pharma Index. For the past few weeks we have been trying to understand how to use the performance of an index reflects in performance of stocks that are constituents of that particular index and vice versa. By catching the index that is on the verge of breaking out or has broken out during the week, we can plan our investment and trades around it to maximize our returns. We spoke about Bank Nifty, then IT Index. Both gave considerable returns in the last 2 /3 weeks. The index that look most interesting this week end is Pharma Index. Pharma index has given a powerful breakout and has closed above very important fibonacci resistance (20380) this week. The closing of Pharma index this week was 20453.85. The next 2 Fibonacci resistances for Nifty will be at 21013 and 21475. Supports for the Pharma index remain at 19936 and 19397. 19397 is a mega support which has a combined power of Fibonacci, Mid-channel and 50 days EMA. The stocks that constitute the Pharma index are: Lupin, Dr.Reddy's Lab, Torrent Pharma, Alkem Lab, Biocon, Divi's Lab, Sun Pharma, Cipla, Zydus Life and Aurobindo Pharma. Some Peripheral Pharma stocks can also be looked at for investment purpose. We are not giving a buy or sell call on any of these companies. This is just an educational article explaining the potential moves of Pharma Index, how it can move in either direction and what can be the technical reasons behind the same. Disclaimer: There is a chance of biases including confirmation bias, information bias, halo effect and anchoring bias in this write-up. Investment in stocks, derivatives and mutual funds is subject to market risks, please consult your investment advisor before taking financial decisions. The data, chart and other information provided above is for the purpose of analysis and is purely educational in nature. The names of the stocks or index levels mentioned in the article are for the purpose of education and analysis only. Purpose of this article is educational. Please do not consider this as a recommendation of any sorts.
NSE:CNXPHARMALong
by Happy_Candles_Investment
Roche Analysis 6/26DISCLOSURE: as of 6/26 I have no open position in SIX:RO Roche is a Swiss based pharmaceutical conglomerate with a diverse range of operations and brands. The company has a long history of profitability and high returns on investment. Management Effectiveness: Roche has been around since 1896 and has had consistent growth over the economic cycles. Return on equity has been averaging 40% and although margins have compressed in recent years the company remains highly profitable and in a stable leverage position. Valuation: With a price to earnings of 20 and price to cash flow of 15 if looks potentially undervalued. I like companies that have a return on equity double that of the price to earnings, and that rule of thumb is met in this case. Summary: Roche looks like a quality company to potentially take some profits and diversify from my NASDAQ:SIGA position. However, for now it will stay on the watch list. I will be looking at OANDA:USDCHF as well as the valuation metrics I mentioned above. Here on my macroeconomic and current research shortlist watchlists: www.tradingview.com www.tradingview.com Thanks for reading, have a good one
SIX:RO
by sihen999
GILD will be selected for the new Tamiflu vaccine for Pandemic2It's no secret the elite are manufacturing pandemics to herd, destroy and remake society into a neofeudal system controlled by social credit scores. The next pandemic will be H1N1 which has already been shared within the news that milk in the markets has trace amounts of (no worry they say!). After the establishment rolls out bird-flu for everyone's summer bingo card - Gilead Sciences, the only company that manufactures Tamiflu with options, will be selected to mass create these new vaccines. The call options on this company are going crazy right now, July, August have a ton of OTM calls being bought, almost like someone is expecting this company to get the greenlight on something major. You could effectively buy .05 OTM calls on this company, but I'd wait a little longer. The TTM squeeze shows the last leg down is being finished. If the market's capitulate a little more, this would be a perfect time to buy those calls for this company.
NASDAQ:GILDLong
by EmptyEternity
1
#PHA/USDT#PHA The price is moving in a bearish channel pattern on the 4-hour frame, and it adheres to it well, and it is expected to break to the upside The price rebounded well from the lower border of the channel at the green support level 0.1650, which is a strong level. We have a tendency to stabilize above the Moving Average 100 We have oversold resistance on the RSI indicator to support the rise, with a downtrend about to break higher Entry price is 0.1900 The first target is 0.2330 The second target is 0.2600 The third goal is 0.2884
Long
by CryptoAnalystSignal
UPDATE: Target Reached Aspen R206.03 - Next target higherSymmetrical Triangle was a a text book trade. The previous trend was up. Price broke above the apex 3/4s in and the momentum continued up. We had further indicators of confirmation for upside to come. Price>20 Price>200 Target 1 R206.03 So what now? Well we can expect somewhat a consolidation, and a potential Cup and Handle to form. Then we have the next target above R221. It might be messy to buy now, but in good time it should present a great opportunity. I'll let you know.
JSE:APNLong
by Timonrosso
Amylyx Stock Down With Over 82%, After Pivotal ALS Drug FailureAmylyx stock ( NASDAQ:AMLX ) crashed Friday, losing almost all of its value, after the company said its approved ALS treatment, Relyvrio, failed in a pivotal study. Patients who received Amylyx Pharmaceuticals' ( NASDAQ:AMLX ) Relyvrio showed no significant difference across multiple markers measuring the severity of amyotrophic lateral sclerosis, the longhand name for ALS. In this disease, nerve cells break down, reducing muscle function. The Food and Drug Administration approved Relyvrio based on a single study in September 2022. But Amylyx ( NASDAQ:AMLX ) continued on with a Phase 3 study. Now, Amylyx ( NASDAQ:AMLX ) is deciding whether to voluntarily pull the drug from the market in the U.S. and Canada. In Canada, it sells under the brand name Albrioza. Technical Analysis On today's stock market, Amylyx ( NASDAQ:AMLX ) stock plummeted 82.9% to 3.36. Shares undercut their 50-day and 200-day moving averages, MarketSurge.com shows. That put shares at a record low. Way Forward For Amylyx Stock? It's important to note that Relyvrio failed to make a difference across multiple measures, including the key goal of the study: improvement on the revised Amyotrophic Lateral Sclerosis Functional Rating Scale. The company tested Relyvrio over 48 weeks. Secondary measures of the study also flopped. Amylyx ( NASDAQ:AMLX ) says it now expects to have the results of its study in Wolfram syndrome patients in the second quarter.
NASDAQ:AMLXShort
by DEXWireNews
Novavax Sees 2024 Sales Flat to Lower, Plummeting By 26.4%In a quest to reclaim lost ground and assert its presence in the competitive COVID-19 vaccine market, Novavax (NASDAQ: NASDAQ:NVAX ) charts a strategic course aimed at improving commercial performance and gaining market share from industry giants Pfizer (PFE.N) and Moderna (MRNA.O). Despite facing headwinds and a larger-than-expected fourth-quarter loss, Novavax ( NASDAQ:NVAX ) remains undeterred in its pursuit of market dominance. Chief Executive John Jacobs acknowledges the company's disappointing performance during the recent vaccination campaign, attributing it to delayed market entry and logistical challenges. However, Jacobs remains resolute in his commitment to enhancing Novavax's competitive positioning and expanding its footprint in the burgeoning vaccine landscape. A key focal point of Novavax's ( NASDAQ:NVAX ) strategy is the pursuit of pre-filled syringes, a format favored by consumers and healthcare providers alike for its convenience and ease of use. Jacobs emphasizes the importance of targeted sales efforts and broad retail availability to drive uptake and accelerate market penetration. Despite near-term revenue challenges, Novavax ( NASDAQ:NVAX ) remains optimistic about its long-term prospects, projecting revenue for 2024 in the range of $800 million to $1 billion. The company's commitment to cost containment and operational efficiency underscores its determination to navigate uncertainties and drive sustainable growth in the years ahead. Novavax's ( NASDAQ:NVAX ) journey has been marked by highs and lows, from soaring market valuations to regulatory hurdles and manufacturing setbacks. However, the company's resilience and adaptability position it well to overcome obstacles and emerge as a formidable player in the global fight against COVID-19. While challenges persist, including lingering doubts about the company's financial viability, Novavax remains focused on execution and delivering value to stakeholders. Jacobs's emphasis on operational improvements and leaner processes reflects a renewed commitment to efficiency and effectiveness in the commercial market. As Novavax ( NASDAQ:NVAX ) embarks on this pivotal phase of its journey, investors and industry observers await eagerly to witness the company's ability to translate strategy into tangible results. With determination, perseverance, and a renewed sense of purpose, Novavax ( NASDAQ:NVAX ) seeks to redefine its narrative and carve out a prominent place in the annals of vaccine innovation.
NASDAQ:NVAX
by DEXWireNews
Pharmaceutical Giants Stocks: Macro Fib SchematicsThe biggest pharma giants are easy to recognize. Johnson and Johnson, Pfizer, Moderna, Merck & Co, Danaher Corp, Thermo Fisher Scientific. All medications and pharmaceutical drugs come out of these drug corporations. Lab equipment, medical research, vaccines, and other life science developments come out of these conglomerate pharma giants. Support and Resistance is clear with these schematics. All clusters are laid over appropriately.
NASDAQ:MRNA
by MichaelBsul
ALKEM Near All time high ALKEM is Near all time high Alkem is in a Rising channel and Resistance is working from last 8 years Stock is facing resistance around 5500 for the further upside Stock need to cross 5500 If stock tanks then we might see level of 3100-3200 3100-3200 is strongest support and one should not miss opportunity to BUY around these levels. Thank You !! Disclaimer : We are not SEBI registered analyst. Do your own research before taking any investment decision.
NSE:ALKEMShort
by FiveCircles